Clinical trial
Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
NCT05984342 is registered in ClinicalTrials.gov with Affiliated Cancer Hospital of Shantou University Medical College as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
- Lead sponsor
- Affiliated Cancer Hospital of Shantou University Medical College
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- August 2, 2023
- Completion date
- June 30, 2029
- Enrollment
- 50 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.